Skip to main content

Bladder Cancer Clinical Trials

Review the bladder cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 185

Testing the Role of DNA Released from Tumor Cells into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Status: Active
Location: 451 locations
Gemcitabine Hydrochloride and Cisplatin in Treating Patients with Invasive Bladder Urothelial Cancer
Status: Active
Location: 381 locations
Comparing the New Anti-cancer Drug Eribulin with Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
Status: Active
Location: 396 locations
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Status: Active
Location: 479 locations
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Status: Active
Location: 77 locations
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Status: Active
Location: 72 locations
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Status: Active
Location: 42 locations
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Status: Active
Location: 24 locations
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Status: Active
Location: 22 locations
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Status: Active
Location: 15 locations
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
Status: Active
Location: 12 locations
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Status: Active
Location: 12 locations
Testing Olaparib in Patients with Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors with DNA-Repair Genetic Changes
Status: Active
Location: 11 locations
Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced and/or Node Positive Urothelial Cancer, The EV-ECLIPSE Trial
Status: Active
Location: 10 locations
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Status: Active
Location: 12 locations
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Status: Active
Location: 10 locations
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Status: Active
Location: 9 locations
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
Status: Active
Location: 10 locations
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Status: Active
Location: 8 locations
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Status: Active
Location: 8 locations
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Status: Active
Location: 9 locations
Pembrolizumab and Bacillus Calmette-Guérin as First-Line Therapy in Treating Participants with High-Risk Non-Muscle-Invasive Bladder Cancer and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma
Status: Active
Location: 7 locations
Nivolumab with or without Ipilimumab before Surgery in Treating Patients with Muscle Invasive Bladder Cancer or High Grade Urothelial Cancer of the Upper Urinary Tract
Status: Active
Location: 7 locations
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
Status: Active
Location: 9 locations
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Status: Active
Location: 8 locations